Details of the Drug

General Information of Drug (ID: DM8AI9U)

Drug Name
Loxapine
Synonyms
Cloxazepine; Dibenzacepin; Dibenzoazepine; Lossapina; Loxapin; Loxapina; Loxapinsuccinate; Loxapinum; Loxepine; Oxilapine; Lossapina [DCIT]; Loxitane IM; CL 62362; HF 3170; HF3170; Hydrofluoride 3170; LW 3170; S 805; SUM 3170; CL-62362; Loxapac (TN); Loxapina [INN-Spanish]; Loxapinum [INN-Latin]; Loxitane (TN); S-805;SUM-3170; CL-71,563; Loxapine (USAN/INN); Loxapine [USAN:BAN:INN]; Loxapine [USAN:INN:BAN]; 2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine; 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,5]benzoxazepine
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 327.8
Topological Polar Surface Area (xlogp) 3.1
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 4 hours [2]
Metabolism
The drug is metabolized via the hepatic [3]
Chemical Identifiers
Formula
C18H18ClN3O
IUPAC Name
8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
Canonical SMILES
CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
InChI
InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3
InChIKey
XJGVXQDUIWGIRW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3964
ChEBI ID
CHEBI:50841
CAS Number
1977-10-2
DrugBank ID
DB00408
TTD ID
D0U5OE
INTEDE ID
DR0989
ACDINA ID
D00379

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [5]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [5]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.36E-01 1.62E-02 1.08E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Loxapine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Loxapine and Quetiapine. Schizophrenia [6A20] [42]
Mesoridazine DM2ZGAN Moderate Additive anticholinergic effects by the combination of Loxapine and Mesoridazine. Schizophrenia [6A20] [42]
Thioridazine DM35M8J Moderate Additive anticholinergic effects by the combination of Loxapine and Thioridazine. Schizophrenia [6A20] [42]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Loxapine and Aripiprazole. Schizophrenia [6A20] [42]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Loxapine and Iloperidone. Schizophrenia [6A20] [42]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Loxapine and Paliperidone. Schizophrenia [6A20] [42]
Haloperidol DM96SE0 Moderate Additive anticholinergic effects by the combination of Loxapine and Haloperidol. Schizophrenia [6A20] [42]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Loxapine and Perphenazine. Schizophrenia [6A20] [42]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Loxapine and Molindone. Schizophrenia [6A20] [42]
Chlorpromazine DMBGZI3 Moderate Additive anticholinergic effects by the combination of Loxapine and Chlorpromazine. Schizophrenia [6A20] [42]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Loxapine and Thiothixene. Schizophrenia [6A20] [42]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Loxapine and Trifluoperazine. Schizophrenia [6A20] [42]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Loxapine and Risperidone. Schizophrenia [6A20] [42]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Loxapine and Asenapine. Schizophrenia [6A20] [42]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Loxapine and Pimozide. Schizophrenia [6A20] [42]
⏷ Show the Full List of 15 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Loxapine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Loxapine and Oliceridine. Acute pain [MG31] [43]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Loxapine and Scopolamine. Addictive disorder [6C50-6C5Z] [42]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Loxapine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [44]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Loxapine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [44]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Loxapine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [42]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Loxapine and Memantine. Alzheimer disease [8A20] [42]
Galantamine DMEO794 Moderate Antagonize the effect of Loxapine when combined with Galantamine. Alzheimer disease [8A20] [45]
Rivastigmine DMG629M Moderate Antagonize the effect of Loxapine when combined with Rivastigmine. Alzheimer disease [8A20] [45]
Donepezil DMIYG7Z Moderate Antagonize the effect of Loxapine when combined with Donepezil. Alzheimer disease [8A20] [45]
Trimethaphan DMHF4IQ Moderate Additive hypotensive effects by the combination of Loxapine and Trimethaphan. Aneurysm/dissection [BD50] [46]
Bepridil DM0RKS4 Moderate Additive hypotensive effects by the combination of Loxapine and Bepridil. Angina pectoris [BA40] [47]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Loxapine and Amyl nitrite. Angina pectoris [BA40] [47]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Loxapine and Nifedipine. Angina pectoris [BA40] [47]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Loxapine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [42]
Promazine DMZAL7W Moderate Additive anticholinergic effects by the combination of Loxapine and Promazine. Appearance/behaviour symptom [MB23] [42]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Loxapine and Desipramine. Attention deficit hyperactivity disorder [6A05] [42]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Loxapine and Cariprazine. Bipolar disorder [6A60] [42]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Loxapine and Loperamide. Bowel habit change [ME05] [48]
Sotalol DML60TN Moderate Additive hypotensive effects by the combination of Loxapine and Sotalol. Cardiac arrhythmia [BC9Z] [47]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Loxapine when combined with Acetylcholine. Cataract [9B10] [49]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Loxapine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [50]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Loxapine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [50]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Loxapine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [50]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Loxapine and Dihydrocodeine. Chronic pain [MG30] [51]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Loxapine and Olopatadine. Conjunctiva disorder [9A60] [52]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Loxapine and Alfentanil. Corneal disease [9A76-9A78] [43]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Loxapine and Remifentanil. Corneal disease [9A76-9A78] [43]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Loxapine and Ethanol. Cystitis [GC00] [52]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Loxapine and Cyclandelate. Dementia [6D80-6D8Z] [47]
Trimipramine DM1SC8M Moderate Additive anticholinergic effects by the combination of Loxapine and Trimipramine. Depression [6A70-6A7Z] [42]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Loxapine and Cyclobenzaprine. Depression [6A70-6A7Z] [42]
Nortriptyline DM4KDYJ Moderate Additive anticholinergic effects by the combination of Loxapine and Nortriptyline. Depression [6A70-6A7Z] [42]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Loxapine and OPC-34712. Depression [6A70-6A7Z] [42]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Loxapine and Clomipramine. Depression [6A70-6A7Z] [42]
Amoxapine DMKITQE Moderate Additive anticholinergic effects by the combination of Loxapine and Amoxapine. Depression [6A70-6A7Z] [42]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Loxapine and Doxepin. Depression [6A70-6A7Z] [42]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Loxapine and Maprotiline. Depression [6A70-6A7Z] [42]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Loxapine and Esketamine. Depression [6A70-6A7Z] [53]
Hyoscyamine DM804UR Moderate Additive anticholinergic effects by the combination of Loxapine and Hyoscyamine. Digestive system disease [DE2Z] [42]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Loxapine and Mepenzolate. Digestive system disease [DE2Z] [42]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Loxapine and Oxybutynine. Discovery agent [N.A.] [42]
Tetrabenazine DMYWQ0O Major Additive antidopaminergic effects by the combination of Loxapine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [54]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Loxapine and Deutetrabenazine. Dystonic disorder [8A02] [55]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Loxapine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [56]
Diphenhydramine DMKQTBA Moderate Antagonize the effect of Loxapine when combined with Diphenhydramine. Episodic vestibular syndrome [AB31] [57]
Guanabenz DM5QWEL Moderate Additive hypotensive effects by the combination of Loxapine and Guanabenz. Essential hypertension [BA00] [47]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Loxapine and Ethacrynic acid. Essential hypertension [BA00] [46]
Bendroflumethiazide DM7EVLC Moderate Additive hypotensive effects by the combination of Loxapine and Bendroflumethiazide. Essential hypertension [BA00] [47]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Loxapine and Phenoxybenzamine. Essential hypertension [BA00] [47]
Guanethidine DM9NSWT Moderate Additive hypotensive effects by the combination of Loxapine and Guanethidine. Essential hypertension [BA00] [47]
Nicardipine DMCDYW7 Moderate Additive hypotensive effects by the combination of Loxapine and Nicardipine. Essential hypertension [BA00] [47]
Mecamylamine DMGQFYB Moderate Additive hypotensive effects by the combination of Loxapine and Mecamylamine. Essential hypertension [BA00] [47]
Benzthiazide DMQWZ0H Moderate Additive hypotensive effects by the combination of Loxapine and Benzthiazide. Essential hypertension [BA00] [47]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Loxapine and Nadolol. Essential hypertension [BA00] [47]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Loxapine and Solifenacin. Functional bladder disorder [GC50] [42]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Loxapine and Tolterodine. Functional bladder disorder [GC50] [42]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Loxapine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [58]
Phentolamine DMXYJOB Moderate Additive hypotensive effects by the combination of Loxapine and Phentolamine. Gangrene [MC85] [47]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Loxapine and Propantheline. Gastric ulcer [DA60] [42]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Loxapine when combined with Isoflurophate. Glaucoma [9C61] [49]
Carteolol DMFMDOB Moderate Additive hypotensive effects by the combination of Loxapine and Carteolol. Glaucoma [9C61] [47]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Loxapine and Brimonidine. Glaucoma [9C61] [59]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Loxapine when combined with Pilocarpine. Glaucoma [9C61] [49]
Spironolactone DM2AQ5N Moderate Additive hypotensive effects by the combination of Loxapine and Spironolactone. Heart failure [BD10-BD1Z] [47]
Prazosin DMCD9YG Moderate Additive hypotensive effects by the combination of Loxapine and Prazosin. Heart failure [BD10-BD1Z] [47]
Eplerenone DMF0NQR Moderate Additive hypotensive effects by the combination of Loxapine and Eplerenone. Heart failure [BD10-BD1Z] [47]
Carvedilol DMHTEAO Moderate Additive hypotensive effects by the combination of Loxapine and Carvedilol. Heart failure [BD10-BD1Z] [47]
Chlorothiazide DMLHESP Moderate Additive hypotensive effects by the combination of Loxapine and Chlorothiazide. Heart failure [BD10-BD1Z] [47]
Furosemide DMMQ8ZG Moderate Additive hypotensive effects by the combination of Loxapine and Furosemide. Heart failure [BD10-BD1Z] [47]
Amiloride DMRTSGP Moderate Additive hypotensive effects by the combination of Loxapine and Amiloride. Heart failure [BD10-BD1Z] [47]
Bumetanide DMRV7H0 Moderate Additive hypotensive effects by the combination of Loxapine and Bumetanide. Heart failure [BD10-BD1Z] [47]
Hydroflumethiazide DMVPUQI Moderate Additive hypotensive effects by the combination of Loxapine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [47]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Loxapine and Acebutolol. Hypertension [BA00-BA04] [47]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Loxapine and Moexipril. Hypertension [BA00-BA04] [47]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Loxapine and Captopril. Hypertension [BA00-BA04] [47]
Penbutolol DM4ES8F Moderate Additive hypotensive effects by the combination of Loxapine and Penbutolol. Hypertension [BA00-BA04] [47]
Methyldopa DM5I621 Moderate Additive hypotensive effects by the combination of Loxapine and Methyldopa. Hypertension [BA00-BA04] [47]
Clonidine DM6RZ9Q Moderate Additive hypotensive effects by the combination of Loxapine and Clonidine. Hypertension [BA00-BA04] [47]
Losartan DM72JXH Moderate Additive hypotensive effects by the combination of Loxapine and Losartan. Hypertension [BA00-BA04] [47]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Loxapine and Nebivolol. Hypertension [BA00-BA04] [47]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Loxapine and Levamlodipine. Hypertension [BA00-BA04] [47]
Fosinopril DM9NJ52 Moderate Additive hypotensive effects by the combination of Loxapine and Fosinopril. Hypertension [BA00-BA04] [47]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Loxapine and TAK-491. Hypertension [BA00-BA04] [47]
Pindolol DMD2NV7 Moderate Additive hypotensive effects by the combination of Loxapine and Pindolol. Hypertension [BA00-BA04] [47]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Loxapine and Fenoldopam. Hypertension [BA00-BA04] [47]
Indapamide DMGN1PW Moderate Additive hypotensive effects by the combination of Loxapine and Indapamide. Hypertension [BA00-BA04] [47]
Benazepril DMH1M9B Moderate Additive hypotensive effects by the combination of Loxapine and Benazepril. Hypertension [BA00-BA04] [47]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Loxapine and Trichlormethiazide. Hypertension [BA00-BA04] [47]
Labetalol DMK8U72 Moderate Additive hypotensive effects by the combination of Loxapine and Labetalol. Hypertension [BA00-BA04] [47]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Loxapine and Diazoxide. Hypertension [BA00-BA04] [47]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Loxapine and Perindopril. Hypertension [BA00-BA04] [47]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Loxapine and Quinapril. Hypertension [BA00-BA04] [47]
Deserpidine DMRH7CV Moderate Additive hypotensive effects by the combination of Loxapine and Deserpidine. Hypertension [BA00-BA04] [47]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Loxapine and Telmisartan. Hypertension [BA00-BA04] [47]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Loxapine and Irbesartan. Hypertension [BA00-BA04] [47]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Loxapine and Hydralazine. Hypertension [BA00-BA04] [47]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Loxapine and Lisinopril. Hypertension [BA00-BA04] [47]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Loxapine and Clevidipine butyrate. Hypertension [BA00-BA04] [47]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Loxapine and Belladonna. Infectious gastroenteritis/colitis [1A40] [42]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Loxapine and Amantadine. Influenza [1E30-1E32] [60]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Loxapine and Propiomazine. Insomnia [7A00-7A0Z] [42]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Loxapine and ITI-007. Insomnia [7A00-7A0Z] [42]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Loxapine and Polyethylene glycol. Irritable bowel syndrome [DD91] [61]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Loxapine and Clidinium. Irritable bowel syndrome [DD91] [42]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Loxapine and Dicyclomine. Irritable bowel syndrome [DD91] [42]
Physostigmine DM2N0TO Moderate Antagonize the effect of Loxapine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [45]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Loxapine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [62]
Propranolol DM79NTF Moderate Additive hypotensive effects by the combination of Loxapine and Propranolol. Migraine [8A80] [47]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Loxapine and Lasmiditan. Migraine [8A80] [63]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Loxapine and Flibanserin. Mood disorder [6A60-6E23] [64]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Loxapine and Thalidomide. Multiple myeloma [2A83] [65]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Loxapine and Phenindamine. Nasopharyngitis [CA00] [42]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Loxapine and Dimenhydrinate. Nausea/vomiting [MD90] [42]
Prochlorperazine DM53SRA Moderate Additive anticholinergic effects by the combination of Loxapine and Prochlorperazine. Nausea/vomiting [MD90] [42]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Loxapine and Promethazine. Nausea/vomiting [MD90] [42]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Loxapine and Cyclizine. Nausea/vomiting [MD90] [42]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Loxapine and Metoclopramide. Nausea/vomiting [MD90] [66]
Lorcaserin DMG6OYJ Moderate Increased risk of hyperprolactinemic effects by the combination of Loxapine and Lorcaserin. Obesity [5B80-5B81] [67]
Metolazone DMB39LO Moderate Additive hypotensive effects by the combination of Loxapine and Metolazone. Oedema [MG29] [47]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Loxapine and Polythiazide. Oedema [MG29] [47]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Loxapine and Levomethadyl Acetate. Opioid use disorder [6C43] [51]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Loxapine and Lofexidine. Opioid use disorder [6C43] [47]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Loxapine and Apraclonidine. Optic nerve disorder [9C40] [59]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Loxapine and Pentazocine. Pain [MG30-MG3Z] [43]
Dextropropoxyphene DM23HCX Major Decreased metabolism of Loxapine caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [68]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Loxapine and Butorphanol. Pain [MG30-MG3Z] [43]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Loxapine and Oxymorphone. Pain [MG30-MG3Z] [43]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Loxapine and Levorphanol. Pain [MG30-MG3Z] [43]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Loxapine and Dezocine. Pain [MG30-MG3Z] [43]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Loxapine and Flavoxate. Pain [MG30-MG3Z] [42]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Loxapine and Nalbuphine. Pain [MG30-MG3Z] [43]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Loxapine and Buprenorphine. Pain [MG30-MG3Z] [69]
Meperidine DMX4GND Major Additive CNS depression effects by the combination of Loxapine and Meperidine. Pain [MG30-MG3Z] [43]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Loxapine and Oxycodone. Pain [MG30-MG3Z] [43]
Pergolide DM14MAE Moderate Antagonize the effect of Loxapine when combined with Pergolide. Parkinsonism [8A00] [70]
Opicapone DM1BKA6 Moderate Antagonize the effect of Loxapine when combined with Opicapone. Parkinsonism [8A00] [70]
Biperiden DME78OA Moderate Antagonize the effect of Loxapine when combined with Biperiden. Parkinsonism [8A00] [57]
Entacapone DMLBVKQ Moderate Antagonize the effect of Loxapine when combined with Entacapone. Parkinsonism [8A00] [70]
Levodopa DMN3E57 Moderate Additive CNS depression effects by the combination of Loxapine and Levodopa. Parkinsonism [8A00] [70]
Pramipexole DMNMW9R Moderate Antagonize the effect of Loxapine when combined with Pramipexole. Parkinsonism [8A00] [70]
Bromocriptine DMVE3TK Moderate Additive hypotensive effects by the combination of Loxapine and Bromocriptine. Parkinsonism [8A00] [70]
Apomorphine DMX38HQ Moderate Antagonize the effect of Loxapine when combined with Apomorphine. Parkinsonism [8A00] [71]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Loxapine and Lindane. Pediculosis [1G00] [72]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Loxapine and Methylscopolamine. Peptic ulcer [DA61] [42]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Loxapine and Terazosin. Prostate hyperplasia [GA90] [47]
Tamsulosin DM5QF9V Moderate Additive hypotensive effects by the combination of Loxapine and Tamsulosin. Prostate hyperplasia [GA90] [47]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Loxapine and Silodosin. Prostate hyperplasia [GA90] [47]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Loxapine and Levomepromazine. Psychotic disorder [6A20-6A25] [42]
Fluphenazine DMIT8LX Moderate Additive anticholinergic effects by the combination of Loxapine and Fluphenazine. Psychotic disorder [6A20-6A25] [42]
Tolazoline DMI40NL Moderate Additive hypotensive effects by the combination of Loxapine and Tolazoline. Pulmonary hypertension [BB01] [47]
Neupro DMHEAB1 Moderate Antagonize the effect of Loxapine when combined with Neupro. Restless legs syndrome [7A80] [70]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Loxapine and Cyproheptadine. Rheumatoid arthritis [FA20] [42]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Loxapine and Fentanyl. Sensation disturbance [MB40] [43]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Loxapine and Sufentanil. Sensation disturbance [MB40] [43]
Papaverine DMCA9QP Moderate Additive hypotensive effects by the combination of Loxapine and Papaverine. Tonus and reflex abnormality [MB47] [47]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Loxapine and Tizanidine. Tonus and reflex abnormality [MB47] [73]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Loxapine and Atropine. Unspecific substance harmful effect [NE6Z] [42]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Loxapine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [42]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Loxapine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [42]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Loxapine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [44]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Loxapine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [42]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Loxapine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [42]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Loxapine and Azatadine. Vasomotor/allergic rhinitis [CA08] [42]
⏷ Show the Full List of 163 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
Butylparaben E00142 7184 Antimicrobial preservative
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 33 E00261 19116 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Edetate calcium disodium E00487 6093170 Complexing agent
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Gelatin E00630 Not Available Other agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium propionate E00445 2723816 Antimicrobial preservative
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 28 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Loxapine 10 mg capsule 10 mg Oral Capsule Oral
Loxapine 25 mg capsule 25 mg Oral Capsule Oral
Loxapine 5 mg capsule 5 mg Oral Capsule Oral
Loxapine 50 mg capsule 50 mg Oral Capsule Oral
Loxapine Succinate eq 10mg base capsule eq 10mg base Capsule Oral
Loxapine Succinate eq 5mg base capsule eq 5mg base Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45.
5 In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
6 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
7 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
8 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
9 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
10 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
11 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
12 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
13 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
14 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
15 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
16 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
17 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
18 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
19 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
20 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
21 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
22 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
23 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
24 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
25 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
26 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
27 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
28 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
29 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
30 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
31 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
32 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
33 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
34 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
35 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
36 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
37 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
38 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
39 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
40 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
41 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
42 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
43 Cerner Multum, Inc. "Canadian Product Information.".
44 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
45 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
46 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
47 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
48 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
49 Multum Information Services, Inc. Expert Review Panel.
50 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
51 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
52 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
53 Cerner Multum, Inc. "Australian Product Information.".
54 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
55 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
56 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
57 Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
58 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
59 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
60 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
61 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
62 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
63 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
64 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
65 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
66 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
67 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
68 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
69 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
70 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
71 Product Information. Apokyn (apomorphine). Mylan Pharmaceuticals Inc, Morgantown, WV.
72 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
73 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.